Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kazdal

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Genes, Chromosomes & Cancer|March 9, 2021
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreasDaniel Schmitz, Daniel Kazdal, Michael Allgäuer, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
British Journal of Cancer|July 23, 2022
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingOlaf Neumann, Timothy C Burn, Michael Allgäuer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2024
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556]Miriam Blasi, Jonas Kuon, Heike Lüders, et al.
JCO Precision Oncology|August 6, 2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung CancerJonas Kulhavy, Katja Maurus, Miriam Blasi, et al.
Genes, Chromosomes & Cancer|October 26, 2019
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysNicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.
Genes, Chromosomes & Cancer|July 31, 2021
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicinePeter Horak, Jonas Leichsenring, Hannah Goldschmid, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Genes, Chromosomes & Cancer|March 9, 2021
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreasDaniel Schmitz, Daniel Kazdal, Michael Allgäuer, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
British Journal of Cancer|July 23, 2022
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingOlaf Neumann, Timothy C Burn, Michael Allgäuer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2024
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556]Miriam Blasi, Jonas Kuon, Heike Lüders, et al.
JCO Precision Oncology|August 6, 2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung CancerJonas Kulhavy, Katja Maurus, Miriam Blasi, et al.
Genes, Chromosomes & Cancer|October 26, 2019
Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assaysNicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.
Genes, Chromosomes & Cancer|July 31, 2021
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicinePeter Horak, Jonas Leichsenring, Hannah Goldschmid, et al.
Pageof 12